Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, a minor UI/version update with no changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check12 days agoChange DetectedA glossary toggle was added to the page, and several textual updates were made, including capitalizing 'Last Update Submitted that Met QC Criteria' and updating the label to 'No FEAR Act Data' with the revision now listed as v3.4.0. The previous entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision update from v3.3.3 to v3.3.4; no substantive changes to study details, eligibility criteria, or results are evident.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded and updated study locations (Colorado, Maryland, Michigan, Ontario, Quebec, Gran Canaria, Madrid) and reorganized site listings. The page revision label changed to v3.3.3.SummaryDifference0.8%

- Check77 days agoChange DetectedUpdated Publications section wording to clarify that publications are provided by the submitting party and pertain to study results. Added template revision indicator Revision: v3.3.2.SummaryDifference0.1%

- Check84 days agoChange DetectedRemoval of the government funding/operating status notice from the page; it does not affect trial details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.